Literature DB >> 16959957

Increased expression of midkine in the rat colon during healing of experimental colitis.

Takafumi Yuki1, Shunji Ishihara, M A K Rumi, Cesar F Ortega-Cava, Yasunori Kadowaki, Hideaki Kazumori, Norihisa Ishimura, Yuji Amano, Nobuyuki Moriyama, Yoshikazu Kinoshita.   

Abstract

Midkine (MK) is a unique growth and differentiation factor that modulates the proliferation and migration of various cells; however, little is known regarding its relationship to intestinal diseases. The aim of this study was to investigate MK expression and its role in dextran sulfate sodium (DSS)-induced colitis in rats. The expressions of MK, receptor-like protein-tyrosine phosphatase (RPTP)-beta, and proinflammatory cytokines were examined in rat colonic tissues after the development of DSS-induced colitis using Northern blotting, immunohistochemistry, and laser-capture microdissection (LCM) coupled with RT-PCR. The effects of MK on the migration of intestinal epithelial cells (IEC-6) were also evaluated in vitro using an intestinal wound repair model. MK expression was significantly increased in damaged colonic mucosa, mainly from day 3 to day 5 after the end of DSS administration, with abundant MK immunoreactive signals detected in submucosal fibroblasts. Expressions of proinflammatory cytokines were most strongly induced on day 1, which preceded the augmentation of MK expression. Results of LCM coupled with RT-PCR clearly indicated RPTP-beta expression in colonic epithelial cells. The migration assay showed that wound repair in the MK-treated groups was accelerated dose dependently. The present results showed for the first time that intestinal inflammation upregulates the MK-RPTP-beta system, which may stimulate mucosal regeneration during the process of healing of colitis. Additional investigations regarding the role of MK may contribute to the development of new options for the treatment of inflammatory bowel diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959957     DOI: 10.1152/ajpgi.00388.2005

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  8 in total

Review 1.  Applications of proteomics in the study of inflammatory bowel diseases: Current status and future directions with available technologies.

Authors:  Philip Alex; Marjan Gucek; Xuhang Li
Journal:  Inflamm Bowel Dis       Date:  2009-04       Impact factor: 5.325

2.  Midkine in vitamin D deficiency and its association with anti-Saccharomyces cerevisiae antibodies.

Authors:  F B Serinkan Cinemre; Hakan Cinemre; Cengiz Karacaer; Birsen Aydemir; Ahmet Nalbant; Tezcan Kaya; Ali Tamer
Journal:  Inflamm Res       Date:  2015-11-13       Impact factor: 4.575

3.  Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer.

Authors:  Gregory E Rice; Tracey A Edgell; Dominic J Autelitano
Journal:  J Exp Clin Cancer Res       Date:  2010-06-03

Review 4.  Midkine in inflammation.

Authors:  Ludwig T Weckbach; Takashi Muramatsu; Barbara Walzog
Journal:  ScientificWorldJournal       Date:  2011-12-27

5.  The impact of ATRA on shaping human myeloid cell responses to epithelial cell-derived stimuli and on T-lymphocyte polarization.

Authors:  Arunima Chatterjee; Péter Gogolak; Hervé M Blottière; Éva Rajnavölgyi
Journal:  Mediators Inflamm       Date:  2015-04-07       Impact factor: 4.711

6.  An optimized method for accurate quantification of cell migration using human small intestine cells.

Authors:  Steffen Nyegaard; Brian Christensen; Jan Trige Rasmussen
Journal:  Metab Eng Commun       Date:  2016-03-15

7.  Elevated plasma midkine and pleiotrophin levels in patients with systemic lupus erythematosus.

Authors:  Guo-Cui Wu; Hui Yuan; Hai-Feng Pan; Dong-Qing Ye
Journal:  Oncotarget       Date:  2017-06-20

8.  Midkine level may be used as a noninvasive biomarker in Crohn’s disease

Authors:  Murat Kekilli; Alpaslan Tanoğlu; Fatih Karaahmet; Zeynal Doğan; Murat Can; Abdurrahim Sayilir; Başak Çakal; Tolga Düzenli; Yavuz Beyazit
Journal:  Turk J Med Sci       Date:  2020-04-09       Impact factor: 0.973

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.